Molecular markers and hepatocellular carcinoma: Lending a helping hand in liver transplantation?

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 3, 2009, Pages 211-213

  Dai, Zhi ^a   Yu, Lei ^a   Zhou, Jian ^a   Qiu, Shuang Jian ^a   Fan, Jia ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALPAIN 1; MESSENGER RNA; MOLECULAR MARKER; RETINOBLASTOMA PROTEIN; SORAFENIB; X LINKED INHIBITOR OF APOPTOSIS; CALPAIN; TUMOR MARKER; XIAP PROTEIN, HUMAN;

ADVANCED CANCER; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER TRANSPLANTATION; METASTASIS; PROGNOSIS; RECURRENCE RISK; TUMOR VOLUME; LIVER TUMOR; METABOLISM; PREDICTION AND FORECASTING; RISK FACTOR; TUMOR RECURRENCE;

CALPAIN; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 68149126521     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.12     Document Type: Editorial

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55(2), 74-108 (2005).
2. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved significantly with time. J. Clin. Oncol. 21(23), 4329-4335 (2003).
3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003).
4. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334(11), 693-699 (1996).
5. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S268-S276 (2004).
6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25(2), 181-200 (2005).
7. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33(6), 1394-1403 (2001).
8. Duffy JP, Vardanian A, Benjamin E et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann. Sug. 246(3), 502-509 (2007).
9. Decaens T, Roudot-Thoraval F, Hadni-Bresson S et al. Impact of UCSF criteria according to pre- and post-OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time. Liver Transpl. 12(12), 1761-1769 (2006).
10. Grasso A, Stigliano R, Morisco F et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive value of nodule size in a retrospective and explant study. Transplantation 81(11), 1532-1541 (2006).
11. Toso C, Asthana S, Bigam DL et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 49(3), 832-838 (2009).
12. Bai DS, Dai Z, Zhou J et al. Capn4 overexpression underlies tumor invasion and metastasis after liver transplantation for hepatocellular carcinoma. Hepatology 49(2), 460-470 (2009).
13. Ramos E, Lladó L, Serrano T et al. Utility of cell-cycle modulators to predict vascular invasion and recurrence after surgical treatment of hepatocellular carcinoma. Transplantation 82(6), 753-758 (2006).
14. Cheung ST, Fan ST, Lee YT et al. Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation 85(1), 81-87 (2008).
15. Schwartz M, Dvorchik I, Roayaie S et al. Liver transplantation for hepatocellular carcinoma: extension of indications based on molecular markers. J. Hepatol. 49(4), 581-588 (2008).
16. Shi YH, Ding-WX, Zhou J et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology 48(2), 497-507 (2008).
17. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
18. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
19. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64(19), 7099-7109 (2004).
20. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).